- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06447480
Randomiserad klinisk studie för att jämföra oralt isotretinoin med standardvård hos patienter med måttlig akne. (ETHNIC)
Randomiserad klinisk studie för att jämföra oralt isotretinoin med standardvård hos patienter med måttlig akne hudfärg: etnisk studie
In Dermatology, assessment of people of color remains underrepresented in RCTs (<10%) and guidelines. Acne affects around 9% of the population worldwide and negatively affects quality of life and self-esteem with anxiety, suicidal ideation and physical scarring. Main lesions associate comedons, inflammatory papules and pustules which grading of severity allows decision-making, e.g., topicals in mild acne and isotretinoin in severe acne. In darker skin type patients, i.e., Fitzpatrick phototypes IV-VI, acne-related pigmentation (ARP) occurs in 65% of cases which reflects either per- or post-inflammatory hyperpigmentation. Whatever is the mechanism, ARP (number, size, importance of dyschromia) impacts the quality of life in such patients. In moderate acne, treatment is based on oral antibiotics for 3 months, i.e., doxycycline or lymecycline, with topical treatment like tretinoin targeting comedons (and potentially ARP). However, oral antibiotics first-line were developed in white skin patients only and never showed its efficacy in ARP. Moreover, doxycycline could be associated with new-onset hyperpigmentation in acne patients. Isotretinoin -acting on the sebaceous gland and therefore the most effective drug in acne- is only prescribed after failure of antibiotics according to the guidelines.The main objective: To assess the superiority at M6 of a treatment of moderate facial acne in skin of color patients with oral isotretinoin in first line compared to the current standard of care on the severity of ARP.Multicenter randomized controlled trial - open study. The number of subjects required for the trial = 420
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Thierry Passeron, PhD
- Telefonnummer: +33492036488
- E-post: passeron.t@chu-nice.fr
Studera Kontakt Backup
- Namn: Emmanuelle Pradelli
- Telefonnummer: +33492036488
- E-post: pradelli.e@chu-nice.fr
Studieorter
-
-
-
Argenteuil, Frankrike
- Rekrytering
- CH D'argenteuil
-
Kontakt:
- Emmanuel MAHE, Ph
- E-post: emmanuel.mahe@ch-argenteuil.fr
-
Underutredare:
- emmanuel Mahé, Ph
-
Brest, Frankrike
- Rekrytering
- Cabinet Dermatologique Brest 1
-
Kontakt:
- Nicolas Jouan, Ph
- E-post: nicole.jouan@wanadoo.fr
-
Underutredare:
- Nicole Jouan, Ph
-
Brest, Frankrike
- Rekrytering
- Cabinet Dermatologique Brest 2
-
Kontakt:
- Martine Schollhammer, Ph
- E-post: Martine.schollhammer@wanadoo.fr
-
Underutredare:
- Martine Schollhammer, Ph
-
Cenon, Frankrike
- Har inte rekryterat ännu
- Cabinet dermatologique Cenon
-
Kontakt:
- Jean-Michel Amici, Ph
- E-post: jmamici@gmail.com
-
Underutredare:
- Jean-Michel Amici, Ph
-
Gradignan, Frankrike
- Rekrytering
- Cabinet dermatologique gradignan
-
Kontakt:
- Sandra Ly, Ph
- E-post: dr.sandra.ly67@gmail.com
-
Underutredare:
- Sandra Ly, Ph
-
La Réunion, Frankrike
- Rekrytering
- CHU de la réunion
-
Kontakt:
- Antoine Bertolotti, PhD
- E-post: antoine_bertolotti@yahoo.fr
-
Underutredare:
- antoine bertolotti, PhD
-
Paris, Frankrike
- Har inte rekryterat ännu
- Cabinet dermatologique privé
-
Kontakt:
- Pierre Schneider, Ph
- E-post: drpierreschneider@gmail.com
-
Underutredare:
- Pierre Schneider, Ph
-
Paris, Frankrike
- Rekrytering
- Ambroise paré
-
Kontakt:
- Tu-Anh Duong, Ph
- E-post: tu-anh.duong@aphp.fr
-
Underutredare:
- Tu-Anh Duong, Ph
-
Paris, Frankrike
- Rekrytering
- Cabinet dermatologique
-
Huvudutredare:
- Christelle Comte
-
Kontakt:
- Christelle Comte
- Telefonnummer: 06.50.72.89.09
- E-post: Dr.ch.comte@gmail.com
-
Paris, Frankrike
- Rekrytering
- CH Avicenne - APHP
-
Kontakt:
- Gérome Bohelay, Ph
- E-post: gerome.bohelay@gmail.com
-
Underutredare:
- Gérôme Bohelay, Ph
-
Poitiers, Frankrike
- Rekrytering
- CHU de Poitiers
-
Kontakt:
- Da Hee Pitaud, Ph
- Telefonnummer: 0549444459
- E-post: Da-hee.pitaud@chu-poitiers.fr
-
Huvudutredare:
- Da Hee Pitaud
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, Frankrike, 06200
- Rekrytering
- CHU de Nice - Hôpital de l'Archet
-
Kontakt:
- Thierry Passeron, PhD
- Telefonnummer: +33492036488
- E-post: passeron.t@chu-nice.fr
-
Huvudutredare:
- Thierry Passeron, PhD
-
-
Aquitaine
-
Bordeaux, Aquitaine, Frankrike, 33000
- Rekrytering
- CHU de Bordeaux
-
Kontakt:
- Marie Beylot-Barry, PhD
- E-post: marie.beylot-barry@chu-bordeaux.fr
-
Underutredare:
- Marie Beylot-Barry, PhD
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, Frankrike, 44 000
- Rekrytering
- CHU de Nantes
-
Kontakt:
- Marie Lemoigne, Ph
- E-post: marie.lemoigne@chu-nantes.fr
-
Underutredare:
- Marie Lemoigne, Ph
-
-
Seine-maritime
-
Rouen, Seine-maritime, Frankrike, 76000
- Rekrytering
- chu de Rouen
-
Kontakt:
- Pascal Joly, PhD
- E-post: pascal.joly@chu-rouen.fr
-
Underutredare:
- pascal joly, PhD
-
-
Var
-
Sainte-Maxime, Var, Frankrike, 83000
- Rekrytering
- Cabinet de dermatologie St Maxime
-
Kontakt:
- Marc Reverte, Ph
- E-post: dr.reverte@orange.fr
-
Underutredare:
- Marc Reverte, Ph
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Frankrike, 75000
- Rekrytering
- APHP
-
Kontakt:
- Coralie Lheure, PhD
- E-post: coralie.lheure@aphp.fr
-
Underutredare:
- Coralie LHEURE, PhD
-
-
-
-
-
Cayenne, Franska Guyana, 97306
- Rekrytering
- CH de Cayenne 3 Avenue Alexis Blaise, BP6006
-
Kontakt:
- Romain BLAIZOT
- Telefonnummer: 0594397799
- E-post: romain.blaizot@ch-cayenne.fr
-
Kontakt:
- william faurous
- Telefonnummer: 0594397799
- E-post: william.faurous <william.faurous@ch-cayenne.fr>
-
Huvudutredare:
- Romain Blaizot
-
Fort-de France, Franska Guyana
- Rekrytering
- Cabinet de dermatologie DERMACLINIC 972
-
Kontakt:
- emilie baubion, Ph
- Telefonnummer: 0767292250
- E-post: dr.emilie.baubion@gmail.com
-
Huvudutredare:
- Emilie Baubion
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Women and men between 13 and 30-year-old
- Skin type IV, V and VI according to Fitzpatrick skin types
- Moderate acne as defined by the French Society of Dermatology recommendations based on ECLA grading https://document.sfdermato.org/groupe/centre-de-preuves/label-recommandations-acne-post-college.pdf)
- Patients must have a cell phone able to take selfies pictures with a minimum definition of 5Mb.
- Signed informed consent
- Affiliation to French social coverage.
Exclusion Criteria:
- Mild and severe acne (ECLA grading : French recommendations) (https://document.sfdermato.org/groupe/centre-de-preuves/label-recommandations-acne-post-college.pdf)
- Past cure of oral isotretinoin
- Past cure of systemic antibiotics for acne in the last 6 months
- Phototype I-III patients
- Abnormal hemogram, liver enzyme, cholesterol, triglycerides at baseline
- Pregnancy: female patient of childbearing potential will undergo a pregnancy test (plasmatic β-hCG)
- Breast-feeding patients
- Refusal of effective contraception for women
- Contra-indications to oral isotretinoin, doxycycline, lymecycline, topical adapalene/tretinoin
- Vulnerable people: adult under guardianship or deprived of freedom
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Drug group
Patients will be followed every month for 6 months in the group isotretinoin. Patients will start at the dose of 0.5 mg/kg/d. If tolerance is poor, the dose could be decrease to 0.25mg/d. After 3 months, following the recommendations the dose could be increase up to 1mg/kg/d depending on the efficacy. |
The dose is usually of 0.5 mg/kg/d. If tolerance is poor, the dose of isotretinoin can be decreased to 0.25 mg/kg/d. After 3 months of treatment, a clinical evaluation is performed. The dose of isotretinoin can be increased up to 1 mg/kg/d depending on the efficacy (ECLA graded as moderated or severe) and tolerance. A total cumulative dose between 120 to 150 mg/kg is recommended. |
|
Aktiv komparator: Doxycycline
Patients will be followed at 3 and 6 months in the group "standard of care". They will be prescribed topical tretinoin or adapalene once daily (every other day if irritation) with doxycycline or lymecycline 100 mg/d. |
Topical retinoic acid (Effederm®) or adapalene cream (Differine®), associated during the 3 first months with doxycycline or lymecycline 100 mg/d. After 3 months, the efficacy is assessed. If acne improved, oral antibiotics are stopped and only the topical treatment is continued. If the ECLA is graded as moderated or severe, isotretinoin should be introduced. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Severity of score acne-related pigmentation
Tidsram: at 6 months
|
To assess the superiority after 6 months of a first line oral isotretinoin treatment of moderate facial acne in skin of color patients compared to the current standard of care on the severity of ARP. |
at 6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Quality of life of patient
Tidsram: at 6 months
|
Quality of life will be evaluated with the Acne-specific Quality of Life questionnaire (Acne-QoL) |
at 6 months
|
|
Number of adverse events
Tidsram: during 6 months
|
A special focus on scars will be performed using an Investigator Global Assessment score (0 no scar, 1 mild scarring, 2 moderate, 3 severe) over the study period. |
during 6 months
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Thierry Passeron, PhD, CHU de Nice, Service de Dermatologie
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Hudsjukdomar
- Akneiforma utbrott
- Talgkörtelsjukdomar
- Hud- och bindvävssjukdomar
- Acne vulgaris
- Organiska kemikalier
- Retinoider
- Karotenoider
- Polyener
- Alkener
- Kolväten, acyklisk
- Kolväten
- Cyklohexener
- Cyklohexaner
- Cykloparaffiner
- Kolväten, alicyklisk
- Kolväten, cykliska
- Terpener
- Pigment, biologiska
- Biologiska faktorer
- Isotretinoin
- Floderm topical cream
Andra studie-ID-nummer
- 22-APN-02
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .